Abstract 2077P
Background
To investigate the efficacy of Superoxide Dismutase (SOD, 70 UI), Palmitoyethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg),vitamins B6 (1.5 mg), B1 (1.1 mg), B12(2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet in managing neuropathic pain due to cancer chemotherapy.
Methods
In this pilot study, 67 age-matched patients with cancer (41 men) and a mean age of 65.4 years were randomly assigned, either to receive the combination of ten elements (2 tablets/24h) in the active A group, (n=33), or the placebo B (n=34) for six months. Nerve function was assessed by DPN Check [sural nerve conduction velocity (SNCV) and amplitude (SNAP)]. Sudomotor function was evaluated with SUDOSCAN, which measures electRochemical skin conductance in hands and feet (ESCH and ESCF). We used Pain questionnaires: Pain Detect (PD), Neuropathic Pain Symptom Inventory (NPSI), and Visual Analog Scale (VAS) for the estimation of neuropathic pain, also. All patients received Taxanes and platinum analogs as cancer chemotherapy.
Results
At follow-up, measurements from SNCV, SNAP, ESCH and ESCF did not change significantly in both groups. In A group PD baseline vs. final (9.57±7.0 vs. 6.78±4.16, p=0.003), NPSI (28.51±21.26 vs. 19.87±12.6, p<0.001) and VAS (27.78±22.40 vs 21.48±17.79, p=0.003) improved significantly during follow up. In group B PD (7.03±5.19 vs. 9.71±6.61 p<0.001), NPSI (23.50±18.99 vs. 36.25±22.15, p<0.001), and VAS (25.03±23.83 vs 38.75±26.60 p<0.001) deteriorated. No side effects detected.
Conclusions
The combination of the ten elements as supplement in one tablet for six months at a daily dose of two pills in patients improved neuropathic pain due to cancer chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06